May 19, 2020
NIH begins clinical trial of hydroxychloroquine, azithromycin for COVID-19 treatment
Editor's Note
The National Institutes of Health (NIH) on May 14 announced that it is enrolling adults with mild to moderate COVID-19 in a study of treatment with hydroxychloroquine and azithromycin.
The Phase 2b trial is enrolling around 2,000 adults across the US. Participants must have confirmed infection with SARS-CoV-2 and be experiencing fever, cough, and/or shortness of breath.
The participants will be randomly assigned to short-term treatment with either hydroxychloroquine and azithromycin or matching placebos.
Free Daily News
- Acknowledging burnout can open discussion for improvement
- Mechanism found to boost muscle injury repair
- Federal program solicits autonomous robotic surgery technology proposals
- Financial hardships a reality for some after surgery
- Marburg virus disease outbreak in Ethiopia sparks alert for readiness in US
- OR Manager Welcomes New Content Director Joe Paone to Lead Brand Into Its Next Chapter
- Health access concerns up
- AI wound care monitor detects infections early
- Leaders need to build human-centered skills
- Trends in US outpatient surgery growth
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement